2023
Multimodeling approach to evaluating the efficacy of layering pharmaceutical and nonpharmaceutical interventions for influenza pandemics
Prasad P, Steele M, Reed C, Meyers L, Du Z, Pasco R, Alfaro-Murillo J, Lewis B, Venkatramanan S, Schlitt J, Chen J, Orr M, Wilson M, Eubank S, Wang L, Chinazzi M, Pastore y Piontti A, Davis J, Halloran M, Longini I, Vespignani A, Pei S, Galanti M, Kandula S, Shaman J, Haw D, Arinaminpathy N, Biggerstaff M. Multimodeling approach to evaluating the efficacy of layering pharmaceutical and nonpharmaceutical interventions for influenza pandemics. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2300590120. PMID: 37399393, PMCID: PMC10334766, DOI: 10.1073/pnas.2300590120.Peer-Reviewed Original ResearchConceptsInfluenza pandemicPandemic influenza scenarioOverall disease burdenIntervention strategiesPandemic influenza modelsNumber of illnessesAntiviral treatmentEffective intervention strategiesDisease burdenPopulation infectionVaccine developmentDisease controlSchool closuresNonpharmaceutical interventionsInfluenza modelVirus spreadEarly spreadEarly implementationPandemic scenarioUniversity of VirginiaHospitalizationPandemicVaccinationGroupVaccine
2015
Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
Alfaro-Murillo JA, Townsend JP, Galvani AP. Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine 2015, 34: 225-229. PMID: 26631416, DOI: 10.1016/j.vaccine.2015.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleMass ScreeningMiddle AgedUnited StatesYoung AdultConceptsVaccine waningVaccine efficacyOptimal ageCMV vaccine candidatesLongitudinal clinical evaluationChild-bearing yearsYears of ageTransmission dynamicsCMV prevalenceCMV vaccinationCytomegalovirus ScreeningSeronegative femalesCongenital infectionCytomegalovirus infectionVaccine protectionSuch vaccinationClinical evaluationClinical trialsHearing lossVaccine candidatesVaccinationDemographic dataCongenital diseaseCognitive deficitsIndirect protection